Dr. Johnathon Anderson analyzes the 2026 GLP-1 discontinuation study. Learn why 50% of patients stop treatment early and the clinical strategy needed to prevent biological depreciation of heart health.

Federal courts blocked the NIH 15% indirect cost cap on Jan 5, 2026. We analyze the 'Industrial Math' of how this ruling saved biotech startups from an IP tax.

In 2024, China surpassed the US in clinical trials (7,100 vs. 6,000). This analysis explores how China is winning by 'industrializing serendipity' to reverse Eroom's Law.

Bruce Booth predicts a 2026 Biotech IPO surge. Learn why 'CMC Risk' and the 'Bioavailability-Adjusted PMI' will separate the winners from the 'Zombie Class' of new issuers.

Novo Nordisk’s launch of Oral Wegovy (25mg/50mg) is a commercial milestone but a manufacturing paradox. With <1% bioavailability using SNAC technology, the 'peptide math' creates an unsustainable API burden. We analyze why next-gen oral delivery vehicles are critical to solving the looming supply cliff.

Is Generative AI ready to replace the wet lab? We analyze the 2026 landscape of autonomous biologics design, diffusion models, and critical gaps in peptide stability.

Why have Semaglutide and Tirzepatide disappeared from peptide websites? We break down the 2026 SAFE Drugs Act, the end of the 'shortage loophole,' and why our strict compliance strategy ensures Peptide Systems remains your stable partner for legitimate research.

Federal funding is stalling, but innovation isn't. Discover why Decentralized Science (DeSci) and agile independent labs are the future of peptide research.

JPM 2026 Alert: We analyze the 3 trends redefining peptide chemistry this week, from MBX’s 'programmable stability' to the new wave of oral delivery. Read the full briefing.

The 2025 M&A rebound signals a new era for biotech: the shift from 'Speed to Data' to 'Data Integrity.' Explore how the 2026 market landscape is redefining R&D priorities, driving demand for higher-purity reagents, and reshaping the supply chain for complex Cell & Gene therapies.

The FDA's guidance on peptide therapies provides recommendations to support the pharmaceutical industry in the development of peptide drugs.

Written by Johnathon Anderson, Ph.D., a research scientist specializing in regenerative medicine and serving as an Associate Professor at the University of California Davis School of Medicine Zepbound vs Wegovy for Weight Loss Eli Lilly's anti-obesity medication, Zepbound , has outperformed Novo Nordisk's Wegovy  in a head-to-head clinical trial, according to data released by Lilly. Zepbound Beats Wegovy in Clinical Trial The study evaluated weight loss outcomes over 72 weeks